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Abstract Anticancer treatment with the human epidermal
growth factor receptor (HER) 2 inhibitors can lead to signif-
icant myocardial dysfunction. The primary aim of the study
was to estimate the possible association between gene expres-
sion in the ErbB signaling pathway and selected clinical event
data in patients with acute heart failure. Twenty-four patients
(19 males), aged 68.6±12.3 years, were diagnosed and treated
due to acute heart failure. The globaltest method was used for
the correlation between blood nuclear cells’ gene expression
in the ErbB pathway (KEGG pathway id 04012) and impor-
tant clinical data. Decreased expression of ErbB2/HER2 was
found to be associated with the release of troponin and the
need for inotropic support, whereas decreased neuregulin 1
(NRG1) expression was found to be associated with a
decrease of ejection fraction below 40 % (globaltest p -value
< 0.05). In summary, the ErbB signaling pathway and, espe-
cially, HER2/ErbB2 receptor expression are significantly as-
sociated with some of the recognized, clinically significant
parameters of patients with acute heart failure. Evaluation of
the molecular function of the HER2 receptor may be essential
for the prognosis and targeted therapy of heart diseases.
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Introduction
The ErbB family is composed of four plasma membrane-
bound receptor tyrosine kinases, which are involved in mo-
lecular signaling related to cell growth and survival in many
tumor types (Motoyama et al. 2002). The human epidermal
growth factor receptor 2, known as HER2 (sometimes as Neu
or ErbB2), is a member of this receptor family.
Targeting the HER2 receptor is a milestone in the treatment
of selected patients with early and advanced breast cancer
(Baselga et al. 2006; Nielsen et al. 2013). Anticancer efficacy
is complicated by a new type of heart failure (Cheng and Force
2010; Perez 2008). There is evidence that trastuzumab
(Criscitiello and Curigliano 2013; Procter et al. 2010;
Russell et al. 2010), lapatinib (Perez et al. 2008a), and
pertuzumab (Lenihan et al. 2012) blocking the ErbB2/
HER2-dependent signaling pathway may lead to the deterio-
ration of left ventricular cardiac function.
Cardio-oncology, a new scientific discipline, aims at trying
to find methods to prevent iatrogenic myocardial dysfunction
during anticancer treatment (Curigliano et al. 2012; Opolski
et al. 2011). The prevention of cardiotoxicity related to anti-
HER2 treatment seems to be essential.
On the other hand, cardiologists should be interested in
what is the role of the molecular signaling pathway dependent
on ErbB2/HER2 in patients with heart diseases.
The primary aim of this study was to estimate the possible
association between gene expression in the ErbB signaling
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The study enrolled 24 patients (19 males) with a history of heart
disease who were admitted to the Cardiology Department of
Warsaw Medical University with the diagnosis of AHF. The
mean age of the patients was 68.6±12.3 years. The pre-existing
heart diseases were: (1) myocardial infarction in 18 cases or (2)
left ventricular hypertrophy with mild mitral insufficiency in 6
cases. Before hospitalization, patients had received appropriate
cardiological treatment: 18 were treated with angiotensin-
converting enzyme inhibitors, 17 with beta-blockers, 10 with
diuretics, another 7 with aldosterone antagonists, 18 with
antiplatelet therapy, and 20 with statins. The causes of AHF
was decompensation of the circulatory system due to: myocar-
dial ischemia (6), fluids overload in previous heart failure (5),
valve dysfunction deterioration (3), pulmonary infection (3),
sudden increase of blood pressure (3), myocarditis (2), and
supraventricular arrhythmia with very fast ventricular rate (2).
The exclusion criteria were: myocardial infarction with ST
elevation as a cause of AHF, pre-hospital cardiac arrest, pulmo-
nary embolism or stroke, cancer or severe lung disease, and
chronic kidney disease in previous history.
All patients were diagnosed and treated according to the
actual guidelines of the European Society of Cardiology.
Chest X-ray was performed in all patients to assess the degree
of congestion in the lungs. The following laboratory tests were
performed in all of the participants: complete blood count,
serum sodium, potassium, urea, creatinine, albumin, liver
enzymes, prothrombin time, and troponin. Doppler echocar-
diography was performed to evaluate the segmental and glob-
al systolic function of the left and right ventricles, diastolic
ventricular function, morphology, and function of the heart
valves.
The study was approved by the local ethics committee of
the Medical University of Warsaw and all participants gave
written informed consent.
RNA isolation, validation, labeling, and hybridization
Blood samples were drawn just after admission to the inten-
sive care unit, before beginning any treatment. They were
obtained from the cephalic vein of the forearm, into
PAXGene tubes (Qiagen, USA). Duplicate samples were
obtained from each patient. Total RNA from peripheral blood
nuclear cells was isolated using a PAXgene Blood RNA kit
(Qiagen, USA). Isolated RNA samples were dissolved in
RNase-free water, and the RNA quantity was measured with
the use of NanoDrop (NanoDrop Technologies, USA).
Samples with an adequate amount of RNAwere treated with
DNase I to eliminate DNA contamination and then purified
using an RNeasy MiniElute Cleanup kit (Qiagen, Germany).
Analysis of the final RNA quality and integrity was performed
with a Bioanalyzer from Agilent Technologies (USA).
The gene expression profile analysis was performed using
SurePrint G3 Hmn GE 8x60K (Agilent Technologies, USA).
Each slide contained eight microarrays representing about
60,000 predicted human mRNAs. Experiments were
performed using a common reference design, where a com-
mon reference was a pool of equal amounts of RNA from all
the patients. On each two-color microarray, we hybridized
100 ng of total RNA isolated from individual patients and
100 ng of total RNA from the pool. Sample labeling,
amplification, and microarray hybridization was performed
with the use of appropriate kits supplied by the manufac-
turer of the microarrays (Agilent Technologies, USA),
according to manufacturer’s protocols (Agilent Technologies,
USA) . The acquisition and analysis of hybridization




The probe data were loess normalized, and probes replicated
in the array were averaged. The log-ratio of the sample to
reference signal was calculated and the data were median-
centered.
Correlation of the expression of genes in the ErbB signaling
pathway with clinical event data
Association of the expression of genes in the ErbB pathway
(Kyoto Encyclopaedia of Genes and Genomes: KEGG path-
way id 04012) with clinical data was analyzed using the
globaltest method (Goeman et al. 2004). The globaltest meth-
od is used to test the null hypothesis of no association of genes
in the pathway with the selected clinical event. We tested
association with the following clinical data observed in 24
patients:
1. Need for inotropic therapy: yes vs. no
2. Pulmonary edema: yes vs. no
3. Standard troponin I level: elevated vs. value in normal
range
4. Ejection fraction of left ventricle (EF): supra- vs.
inframedian
5. Duration of hospitalization (days): supra- vs. inframedian
6. 30 days follow-up: improvement vs. no improvement to
NYHA class I/II
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The analyses were performed with the globaltest R/
Bioconductor package. The significant genes were selected
based on the globaltest p -value < 0.05.
Results
At the time of admission to the intensive care unit, before
beginning any treatment, nine patients were recognized with
pulmonary edema diagnosis and seven patients needed ino-
tropic therapy. Moreover, 11 patients had elevated levels of
troponin. The baseline hemodynamic parameters were
recorded: (1) blood pressure: median = 140/70 mmHg [range:
60/40–200/120]; (2) heart rate: median = 115/min [range 95–
160 ]; (3) NTproBNP: median = 6,550 pg/ml [range: 1,100–
17,700].
Biplane volume determination by two-dimensional echo-
cardiography was used to evaluate the left ventricular ejection
fraction and EF = 40 % was the median value [range: 15–
56 %]. A period of 12 days resulted as the median value of
hospitalization time, with a range between 5–58 days. It
means that 12 patients needed hospitalization longer than
12 days. During 30 days of observation, 12 patients have
experienced improvement to NYHA class I/II.
Analysis of the association of the expression of genes in the
ErbB pathway with selected clinical data of patients revealed a
significant association of some ErbB genes with the troponin
level, ejection fraction, and need for inotropic therapy
(Table 1). The significant genes were selected based on the
globaltest p -value < 0.05 (Table 2).
Analysis of the association of the ErbB pathway genes with
the troponin level revealed that patients with an elevated level of
troponin have decreased expression of two genes, namely,
ERBB2 and AKT (phosphoinositide 3-kinase, PI3K, the signal-
ing pathway activated by HER2) (see Fig. 1: expression signal
below 0), whereas in patients with a low troponin level, ERBB2
and AKT are upregulated (see Fig. 1: signal is above 0).
Analysis of the association of the ErbB pathway genes with
ejection fraction value revealed that patients with ejection
fraction >40 % have higher expression signal of neuregulin
1 (NRG1) (see Fig. 2: expression signal above 0), whereas in
patients with ejection fraction <40%,NRG1 is downregulated
(see Fig. 2: this signal is below 0). Of interest is that the
microarray contained two different probes of NRG1, and both
of them have the same expression pattern.
Analysis of the association of the ErbB pathway genes with
inotropic therapy revealed nine genes which differed in ex-
pression in patents with and without the need for inotropic
therapy. The largest differences were observed in the cases of
transforming growth factor alpha (TGFA) and AKT1.
Analysis of the association of the ErbB pathway genes in
“high-risk patients” was represented by two or three out of the
following: low EF, need for inotropic therapy, elevated troponin
level (10 patients, see Table 1), which appeared to significantly
decrease the expression of two genes (see Fig. 4). One of these
two genes is ERBB2, with expression signal below 0.
Discussion
The ErbB family of receptor tyrosine kinases couples the
binding of extracellular growth factor ligands to intracellular
Table 1 Characteristics of the patients according to the assumptions of
the study. The presented troponin level, ejection fraction, and need for
inotropic therapy were found to be significantly associated with some
ErbB genes expression






1 Yes Yes Yes
2 Yes Yes Yes
3 Yes Yes Yes
4 Yes Yes No
5 Yes Yes No
6 Yes Yes No
7 Yes Yes No
8 Yes Yes No
9 Yes No Yes
10 Yes No No
11 Yes No No
12 No Yes Yes
13 No Yes No
14 No Yes No
15 No Yes No
16 No No Yes
17 No No Yes
18 No No No
19 No No No
20 No No No
21 No No No
22 No No No
23 No No No
24 No No No
Table 2 Genes from the ErbB pathway were significantly associated
with troponin level, ejection fraction value, and the need for inotropic
therapy in patients with acute heart failure




Inotropic therapy 2064, 5296, 5609, 207, 5294, 2475,
6464, 1950, 7039
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signaling pathways, regulating diverse biologic responses,
including proliferation, differentiation, cell motility, and sur-
vival. One of the fourmembers of this family is ErbB2(HER2)
and the HER2/ErbB2-dependent signaling pathway is proba-
bly responsible for the proper myocardium structure, contrac-
tility, and function, despite the negative influence of ischemia,
inflammation, hypertension, or toxins (Negro et al. 2004;
Sawyer et al. 2002; Chien 2006). The HER2 receptor is
responsible for the activation of transcription factor AP-1
(involved in heart muscle hypertrophy) and nuclear factor
kappa B (involved in the response to oxidative stress)
(Speyer 2002). Molecular studies indicate that ErbB2 plays a
key role in dilated cardiomyopathy prevention (Crone et al.
2002). Mice with ErbB2 gene deletion exhibit gradually de-
veloping systolic heart dysfunction with heart ventricles dis-
tension and myocardium thinning (Ozcelik et al. 2002).
However, the binding of neuregulin-1 (NRG-1) to the HER2
receptor is cardioprotective in mice (Liu et al. 2005).
The wide use of anti-HER2/ErbB2 therapies (trastuzumab,
lapatinib, pertuzumab) in oncology resulted in a huge increase
of iatrogenic cardiac dysfunction or heart failure in patients
with breast cancer. The most dramatic data were reported by
Seidman et al. (2002), who showed that trastuzumab admin-
istered simultaneously with cardiotoxic doxorubicin resulted
in significant systolic myocardial dysfunction in every third
woman. The trastuzumab-induced heart failure poses a few
important features. Firstly, the clinical effect is not dose-
dependent and the disease level is variable, from subclinical
decrease in the left ventricle ejection fraction to end-stage
heart failure with signs of NYHA class IV. This has also been
shown in HERA (Suter et al. 2007), NSABP B31 (Tan-Chiu
et al. 2005), and N9831 studies (Perez et al. 2008b). Secondly,
no ultrastructural changes in heart muscle has been observed
(Ewer et al. 2002; Valero et al. 2004). Thirdly, in the majority
of patients, the systolic heart dysfunction is reversible (Ewer
et al. 2005). Sometimes, the normalization of systolic heart
function occurs spontaneously after anti-HER-2 drugs with-
drawal, but, in many cases, pharmacological treatment is
required (Szmit et al. 2010).
The presence of cardiologic complications after anti-HER2
drugs use in oncologic patients requires the clarification of at
least three aspects of this therapy, namely: if HER-2 receptor
plays an important role in cardioprotection, so why do not all
patients experience heart failure during anti-HER2 therapy?
Why do we not see the dose-dependent action of the drug and
the clinical picture could differ in intensity of clinical signs?
ProbeName GeneID p-value abbreviation Full name 
A_23_P89249    2064 0.02235663 ERBB2 
(HER2) 
v-erb-b2 erythroblastic leukemia viral oncogene homolog 
2, neuro/glioblastoma derived oncogene homolog 
A_33_P3400171    208 0.03680284 AKT2 v-akt murine thymoma viral oncogene homolog 2 
Fig. 1 Expression of genes in the ErbB pathway were significantly
associated with the troponin level. Group 1 (yellow ) represents the
expression of a gene in the group of patients who show elevated level
of troponin; group 2 (green) represents patients with low troponin level.
The genes shown in this figure realize globaltest p-values < 0.05. The
“whiskers” extend to the most extreme data point which is no more than
1.5 times the interquartile range (IQR) from the box. If a point lies further
than 1.5 times the IRQ, then it is marked with a circle (and can be
considered an outlier)
ProbeName GeneID p-value abbreviation Full name 
A_33_P3284345    3084 0.009922042 NRG1 neuregulin1 
A_23_P315815    3084 0.016025443 NRG1 neuregulin1 
Fig. 2 Expression of genes in the ErbB pathway significantly associated
with the ejection fraction value. Group 1 (yellow) represents the expres-
sion of a gene in the group of patients who show a level of EF of at least
40; group 2 (green) represents patients with EF level below 40. The genes
shown in this figure realize globaltest p-values < 0.05
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And, finally, why after the anti-HER2 drug discontinuation,
do not all the patients experience the full normalization of
ejection fraction of the left ventricle?
The answer may be found in the study of Cardinale et al.
(2010), who showed that trastuzumab administration could
induce myocardial damage, resulting in increased plasma
troponin level. These results show also that, probably, we do
not know all the aspects of HER-2 inhibition in oncology.
That is why we decided to approach this issue differently and
check whether the clinical picture of patients with AHF is
associated with ErbB2/HER-2 pathway activity. In the present
study, we were able to correlate some clinical features with the
differential expression of some genes involved in the ErbB
pathway in patients with AHF. The measurement of the gene
expression were performed using DNA microarrays, so it is
only semi-quantitative analysis; however, it allowed not only
for the correlation of individual clinical parameters with the
specific gene(s), but also for the verification as to whether the
changes in clinical parameters are associated with increased or
decreased expression of specific gene(s).
Although our patients were not receiving either trastuzumab
or lapatinib, we were able to observe the similar clinical situation
as seen during anti-HER2 treatment. In patients with AHF and
increased troponin level, the ErbB2(HER2) expression is also
decreased (Fig. 1). We do not know, however, the sequence of
these phenomena, whether troponins release was the cause or the
consequence of decreased ErbB2 expression. Since trastuzumab
administration inhibits the ErbB2 expression and this inhibition
results in troponins release possibly in some patients beforeAHF,
there was an unspecific decrease in ErbB2 expression and when
they experienced AHF, they released a high level of troponin. In
our patients with low troponin level, in the range of normal
values, the ErbB2/HER2 expression was unchanged (or slightly
increased). So the main question remains open: why do patients
with high troponin level have decreased ErbB2/HER2 expres-
sion? It is also worth noting that the decreased ErbB2/HER-2
expression was significantly associated with the need for inotro-
pic therapy (Fig. 3). Moreover, the decreased ErbB2/HER-2
expression characterized the “high-risk patients” with two or
three of the following observed clinical events simultaneously:
low EF, need for inotropic therapy, elevated troponin level
(Fig. 4).
ProbeName GeneID p-value abbreviation Full name 
A_23_P89249    2064 0.01275962 ERBB2 
(HER2) 
v-erb-b2 erythroblastic leukemia viral oncogene homolog 
2, neuro/glioblastoma derived oncogene homolog 
A_33_P3367855    5296 0.01604003 PIK3R2 phosphoinositide-3-kinase, regulatory subunit 2 (beta) 
A_33_P3236651    5609 0.01735023 MAP2K7 mitogen-activated protein kinase kinase 7 
A_33_P3275235    207 0.02362099 AKT1 v-akt murine thymoma viral oncogene homolog 1 
A_33_P3304170    5294 0.02390056 PIK3CG phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic 
subunit gamma 
A_23_P34606    2475 0.04074415 MTOR mechanistic target of rapamycin (serine/threonine 
kinase) 
A_24_P68585    6464 0.04229519 SHC1 SHC (Src homology 2 domain containing) transforming
protein 1 
A_23_P155979    1950 0.04727998 EGF epidermal growth factor 
A_23_P377291    7039 0.04813916 TGFA transforming growth factor alpha 
Fig. 3 The expression of genes in the ErbB pathway was significantly
associated with inotropic therapy. Group 1 (yellow) represents the ex-
pression of a gene in the group of patients with no inotropic therapy;
group 2 (green) represents patients with inotropic therapy. The genes
shown in this figure realize globaltest p-values < 0.05
ProbeName GeneID p-value abbreviation Full name 
A_23_P89249   2064 0.01038063 ERBB2 (HER2) v-erb-b2 erythroblastic leukemia viral 
oncogene homolog 2, neuro/glioblastoma 
derived oncogene homolog 
A_23_P308603   6714 0.01687726 SRC v-src sarcoma (Schmidt-Ruppin A-2) viral 
oncogene homolog (avian)  
Fig. 4 The expression of genes in the ErbB pathway in “high-risk
patients” (yellow) is represented by two or three out of the following:
low EF, need for inotropic therapy, elevated troponin level (n =10 pa-
tients, see Table 1). For comparison, “low-risk patients” (green) were
characterized by none or only one of the mentioned clinical events. The
genes shown in this figure realize globaltest p-values<0.05
J Appl Genetics (2013) 54:447–453 451
As mentioned earlier, the binding of neuregulin-1 (NRG-1)
to the HER-2 receptor has cardioprotective action. There are
suggestions that NRG1 may become a new drug for the treat-
ment of heart failure (Jabbour et al. 2011; Yan and Morgan
2011). Ky et al. (2009) presented that circulating NRG-1beta
was significantly elevated in patients with worse chronic heart
failure severity.Moreover, circulating NRG-1beta together with
natriuretic peptide may provide better risk stratification than
each biomarker individually.
The cardioprotective action of NRG-1 is also clearly seen
in our study, since we identified an association between low
NRG-1 expression and decreased ejection fraction below
40 % (Fig. 2). In oncological patients, the decrease of ejection
fraction below 40 is a factor requiring anti-HER-2 therapy
withdrawal. Based on our study, we could conclude that EF
<40 % is associated with decreased expression of NRG1 and
the lack of the cardioprotective action of this molecule. The
patient characteristics (Table 1) show that, between 11 patients
with increased troponin level and molecularly decreased
ErbB, simultaneously, eight patients also have decreased ejec-
tion fraction below 40 % and molecularly decreased NRG1.
The simultaneous presence of EF <40 % and increased tropo-
nin level suggest severe myocardial damage and increased
risk of death/ worse prognosis. Our studies suggest that this
clinical picture is associated with decreased expression of
ErbB and neuregulin-1 (NGR-1) on the molecular level. It
means that, in some of our patients, the occurrence of AHF
changed the expression of the ErbB pathway comparably to
the anti-HER2 treatment. So, we hypothesize that the changes
in ErbB pathway expression (decreased ErbB and NRG1
expression) could be the marker of heart dysfunction not only
in oncological patients but also in otherwise healthy popula-
tion. The molecular function of HER2 receptor should be-
come an essential factor in the prognosis and planning of
targeted prevention of myocardial damage.
The presented study has some important limitations. First
of all, the obtained results were gathered from a very low
number of patients and there is no real control group. It is true
that the recruitment of patients with AHF into clinical trials is
very difficult. The rhetorical question is how to define a
control group: AHF without history of heart disease or com-
pensated chronic heart failure? Second, patients from daily
practice were observed and analyzed, so there were no strong
exclusion criteria. It means that a heterogeneous group of
patients was recruited. There were different reasons for the
occurrence of AHF, which may be associated with possible
differences in gene expression (ischemic vs. infectious vs.
hemodynamic reasons). On the other hand, it is interesting
that the expression of ErbB2/HER2 and its mediator (NRG1)
achieved such a statistically significant level. The presented
results need multicenter future research with the evaluation of
clinical importance in long-term follow-up.
Conclusions
Our study showed that the ErbB signaling pathway and,
especially, ErbB2/HER2 receptor expression are significantly
associatedwith some clinical parameters of patients with acute
heart failure. Decreased expression of ErbB2/HER2 is associ-
ated with the release of troponins and the need for inotropic
therapy, whereas decreased NRG1 expression is associated
with a decrease of ejection fraction below 40%. Therefore, we
could conclude that the measurement of the expression of
genes belonging to the ErbB signaling pathway could become
the prognostic factor not only in patients undergoing antican-
cer anti-HER2 therapy, but in all patients with heart diseases.
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